Azitra shares surge 59.91% after-hours after securing $31.4M financing for cosmetic market expansion.

Azitra Inc. surged 59.91% in after-hours trading following the announcement of a $31.4 million private placement financing, including an initial $10.5 million in convertible preferred stock and up to $20.9 million via warrant exercises. The funding, led by institutional investors and the CEO, will accelerate the development of filaggrin-based proteins and peptides for the cosmetic and cosmeceutical markets, leveraging the company’s genetic engineering platform. The transaction, set to close on March 20, 2026, underscores Azitra’s strategic pivot into a high-growth $3.7 billion biotech cosmetic ingredients market by 2030. The CEO highlighted the technology’s potential to address skin conditions like eczema and aging, signaling near-term commercialization opportunities. The deal’s structure, featuring warrants exercisable at $0.123 per share, and participation from key stakeholders reinforced investor confidence in the company’s expanded market prospects.